GlassScriptPhysician profile
Abigail Catherine Hall
NPI 1437704699
$1,309.75
in general payments reported to CMS, 2019-2025
20 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.68 · 2023: $372 · 2024: $474 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $145.18 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Globus Medical, INC. | $144.40 | 2023 | Excelsiusgps Robotic Navigation System |
| Shield Therapeutics INC | $88.88 | 2023-2024 | Accrufer |
| Pfizer INC. | $57.41 | 2025 | |
| Exact Sciences Corporation | $54.68 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $51.01 | 2024-2025 | |
| Optinose US, INC. | $36.28 | 2024-2025 | |
| Edwards Lifesciences Corporation | $36.11 | 2025 | Sapien 3 Ultra Resilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.66 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $29.77 | 2023-2024 | Jardiance, Zepbound |
| Gt Medical Technologies, INC | $29.68 | 2022 | |
| Amgen INC. | $27.44 | 2023-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.80 | 2024 | Jardiance |
| Verona Pharma, INC. | $21.75 | 2025 | Ohtuvayre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.15 | 2023 | Verquvo, Belsomra |
| Xeris Pharmaceuticals, INC. | $17.57 | 2025 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $16.54 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $16.34 | 2024 | Shingrix |
| Idorsia Pharmaceuticals US INC | $14.07 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.